Yes, I do believe it is more likely a JV with a Japanese's big name company. The chance of capital injection may be low, as BRM has 100+ million cash.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
